Pharmafile Logo

News and Press Releases

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration

Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025

Capsida Biotherapeutics
info@capsida.com
1300 Rancho Conejo Blvd. Thousand Oaks, CA 91320

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors

Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership Valiltramiprosate/ALZ-801 Has Potential to Become the First Oral Agent to Slow Alzheimer’s Pathology in Patients APOLLOE4 Pivotal Phase...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 7, 2025

Alzheon
111 Speen Street, Suite 306 Framingham, MA 01701

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months No delayed...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 8, 2024

Arcellx
info@arcellx.com
800 Bridge Parkway Redwood City, CA 94065

RHYTHM AI announces FDA clearance of the commercial release version of STAR Apollo Mapping System

First-in-human cases successfully completed using this new system at Baptist Health, Jacksonville, Florida 23 September 2024, – London, UK – RHYTHM AI Ltd (“RHYTHM AI” or “the Company”), a UK...

Category: Biotechnology, Clinical Trials
Posted: September 23, 2024

Rhythm AI
info@rhythm-ai.com

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 17, 2024

AC Immune
info@acimmune.com
EPFL Innovation Park-Building B 1015 Lausanne / Switzerland

Asceneuron Secures $100m Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK...

Category: Biotechnology, Clinical Trials, Other
Posted: July 16, 2024

Asceneuron SA
asce-contact@asceneuron.com
Asceneuron SA, EPFL Innovation Park, Bâtiment B, CH-1015 Lausanne, Switzerland

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

Allyx Therapeutics
info@allyxthera.com
555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research

Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis 07 May 2024 -- Cambridge and London,...

Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024

Broken String Biosciences
info@brokenstringbio.com
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR

Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial

Treatment for rare childhood disease was well tolerated and slowed loss of motor function 20 March 2024 -- Maryland, US -- An investigational gene therapy for a rare neurodegenerative disease...

Category: Clinical Trials, Drug Discovery
Posted: March 20, 2024

National Institute of Health (NIH)
olib@od.nih.gov
9000 Rockville Pike Bethesda, Maryland 20892